araag2/HINT huggingface dataset:
Clinical trial NCT00306189 (phase 2, status: completed)
Conditions: osteoporosis
ICD codes: M81.6, Z82.62, Z13.820, M81.8, Z87.310, M81.0, M80.80XS
Drugs: 100 mg amg 162, 60 mg amg 162, 14 mg amg 162, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria: - Ambulatory postmenopausal women. - BMD values (g/cm2, Hologic) must
        be lower than 0.714 at lumbar spine, 0.515 at femoral neck, 0.588 at total hip. - BMD
        values must not be lower than 0.535 at the lumbar spine, 0.406 at the femoral neck and
        0.478 at the total hip. Exclusion Criteria: - Oral bisphosphonate treatments, PTH or PTH
        derivatives use within the last 12 months and administration of any of anti-osteoporotic
        treatments within the last 3 months before initial administration of the investigational
        product. - History of hypocalcemia. - More than two moderate vertebral fractures or any
        severe vertebral fracture.
Clinical trial NCT00766636 (phase 2, status: terminated)
Conditions: pancreatic cancer
ICD codes: C25.3
Drugs: gemcitabine, erlotinib
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          1. Cytologic or histologic proof of adenocarcinoma of the pancreatic head or uncinate
             process is required prior to treatment. Islet cell tumors are not eligible.

          2. Patients must be staged with a physical exam, CXR, and contrast-enhanced CT. Only
             potentially resectable patients are eligible. Potentially resectable defined as: a) no
             extra pancreatic disease, b) no evidence (on CT) of tumor extension to the celiac axis
             or SMA, and c) no evidence (CT or angiogram) of occlusion of the SMV or SMPV
             confluence. Visceral angiography is optional. Laparoscopic staging is not part of the
             pretreatment evaluation for this study. Laparoscopy may be performed prior to planned
             laparotomy at surgeon's discretion. Staging needs to be done within 28 days of
             enrollment.

          3. Patients cannot have known hepatic or peritoneal metastases detected by ultrasound
             (US), CT scan, or laparotomy prior to treatment

          4. There will be no upper age restriction; patients with Karnofsky performance status
             greater than 70 are eligible.

          5. Adequate renal, and bone marrow function: • Leukocytes >= 3,000/uL • Absolute
             neutrophil count >= 1,500/uL • Platelets >= 100,000/Ul • Serum creatinine <= 2.0 mg/dL

          6. Hepatic function (endoscopic or percutaneous drainage as needed) • Total bilirubin < =
             2 X institutional upper limits of normal (ULN) • AST (SGOT)/ALT (SGPT) <= 5 X
             institutional ULN

          7. Patients must have no fever or evidence of infection or other coexisting medical
             condition that would preclude protocol therapy.

          8. Pregnant women with a positive (blood B-HCG) pregnancy test are excluded from this
             study; women of childbearing potential (defined as those who have not undergone a
             hysterectomy or who have not been postmenopausal for at least 24 consecutive months)
             must agree to practice adequate contraception and to refrain from breast feeding, as
             specified in the informed consent.

          9. Patients must sign a study-specific consent form, which is attached to this protocol.

        Exclusion Criteria:

          1. Tumors in the body or tail of the pancreas (to the left of the portal -SMV confluence)
             are not eligible.

          2. Unstable angina or New York Heart Association (NYHA) Grade II or greater congestive
             heart failure

          3. Known presence of central nervous system or brain metastases

          4. Inability to comply with study and/or follow-up procedures

          5. Patients < 18 years of age.
Clinical trial NCT00090766 (phase 2/phase 3, status: completed)
Conditions: cytomegalovirus infections
ICD codes: P35.1
Drugs: valganciclovir [valcyte]
SMILES: CC(C)[C@H](N)C(=O)OCC(CO)OCN1C=NC2=C1NC(N)=NC2=O
Eligibility criteria:

        Inclusion Criteria:

          -  patients between 3 months and 16 years of age;

          -  first solid organ transplant (eg, kidney, liver, heart);

          -  able to tolerate oral medication;

          -  females of childbearing potential must agree to utilize an effective method of
             contraception throughout the study and for 90 days following discontinuation of study
             drug;

          -  patients at risk of developing CMV disease (all transplant recipients other than those
             who are D-R- for CMV).

        Exclusion Criteria:

          -  patients who have previously participated in this study;

          -  patients who are participating in another clinical trial (except with the approval of
             the Sponsor);

          -  severe, uncontrolled diarrhea (more than 5 watery stools per day);

          -  pregnant or lactating females.
Clinical trial NCT00192075 (phase 2, status: completed)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: gemcitabine, avastin, 5fu/folinic acid, oxaliplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have a histological or cytological diagnosis of the colon or rectum with
             Stage III unresectable or Stage IV disease.

          -  Urinalysis or Urine dipstick for proteinuria of less than 1+ (i.e. either 0 or trace).
             If urine dipstick is greater than 1+, the 24 hour urine protein must demonstrate less
             than 500 mg of protein in 24 hours to allow participation.

          -  No prior chemotherapy, immunotherapy, or hormonal treatment for metastatic disease is
             acceptable. However, one prior neo-adjuvant or adjuvant treatment is acceptable,
             including Capecitabine, Camptothecin-11 (CPT-11), 5 Fluorouracil/Leucovorin (5FU/LV)
             or Radiation containing regimens, (but no Oxaliplatin), and only if progression > 6
             months since last adjuvant treatment.

          -  Prior radiation therapy, including radiation to the whole pelvis, is allowed (Cristy
             and Eckerman 1987) and patients must have recovered from the acute toxic effects of
             the treatment prior to study enrollment. Prior palliative radiation therapy given to a
             non-measurable diagnostic site is acceptable if given > 4 weeks prior to treatment or
             if other non-irradiated measurable disease is present.

          -  No known central nervous system (CNS) metastasis.

        Exclusion Criteria:

          -  Histology other than adenocarcinoma

          -  Tumors that demonstrate free perforation as manifested by free air or free fluid in
             the abdomen. Patients with walled-off perforation are eligible.

          -  Gastroduodenal ulcer determined as active by endoscopy.

          -  Invasive procedures defined as follows; major surgical procedures, open biopsy, or
             significant traumatic injury within 28 days prior to randomization, anticipation of
             need for major surgical procedure during the course of study, core biopsy or other
             minor procedure within 7 days prior to registration.

          -  Following cardiac condition; New York Heart Association (NYHA) Class III or IV,
             myocardial infarction (MI) within 6 months, unstable angina within 6 months and
             current symptomatic arrhythmia.
Clinical trial NCT00630500 (phase 2, status: completed)
Conditions: dementia associated with parkinson's disease, dementia with lewy bodies
ICD codes: G31.83
Drugs: memantine, placebo
SMILES: CC12CC3CC(C)(C1)CC(N)(C3)C2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  a diagnosis of Parkinson's disease (Larsen and Dupont, 1994) and dementia (DSM
             IV(1987; 1994), or Dementia with Lewy bodies (McKeith et al. Neurology 2005)

          -  mild-to-moderate or moderate dementia (i.e. MMSE 12-26, inclusive)

          -  the subject has given a written informed consent

          -  the subject is able and willing to comply with the study procedures and has a reliable
             caregiver (i.e. relative or nurse/nurse assistant who sees the patient at least
             weekly)

        Exclusion Criteria:

          -  other brain disease of sufficient severity to cause dementia

          -  mental retardation

          -  terminal illness with life expectancy shorter than 6 months

          -  recent major changes in health status

          -  known epilepsy or previous convulsive seizure

          -  major depression

          -  severe dementia as defined by a Mini-mental State Examination score of 12 or lower

          -  moderate to severe renal impairment (i.e. serum creatinine > 1,5 upper limit normal
             (ULN) or creatinin clearance < 40ml/minute/1,73 m2

          -  moderate or severe heart disease (NYHA III-IV)

          -  moderate or severe pulmonal disease

          -  moderate to severe hepatic impairment (bilirubin or transaminases > 2 times ULN

          -  women of childbearing potential (i.e. not post-menopausal and not taking contraceptive

          -  the subjects is lactating

          -  any laboratory value(s) exceeding the limits of normality if deemed to be clinically
             relevant by the study physician

          -  known allergies to the investigational product
Clinical trial NCT00616785 (phase 2, status: unknown status)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: cisplatin, etoposide, irinotecan hydrochloride
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)

               -  Stage IIIA (N2) or IIIB disease

                    -  Pathologic documentation of N2-3 mediastinal lymph nodes is encouraged but
                       not required if nodal size is ≥ 1.5 cm in largest diameter

                    -  No stage IIIB disease with malignant pleural effusion or superior sulcus
                       tumor

          -  At least one measurable lesion as defined by Response Evaluation Criteria in Solid
             Tumors

          -  Unresectable disease

          -  No known brain metastasis

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Life expectancy > 3 months

          -  ANC ≥ 1,500/mm³

          -  Hemoglobin ≥ 9.0 g/dL (can be corrected by transfusion)

          -  Platelet count ≥ 100,000/mm³

          -  Creatinine < 1.5 mg/dL

          -  Total bilirubin < 2 times upper limit of normal (ULN)

          -  Transaminases < 3 times ULN

          -  Patient compliance and geographic proximity that allow adequate follow up

          -  No serious, uncontrolled systemic intercurrent illness (e.g., infections or poorly
             controlled diabetes)

          -  No history of significant neurological or mental disorder, including seizures or
             dementia

          -  No other malignancy within the past 5 years except carcinoma in situ of the cervix or
             nonmelanoma skin cancer

          -  No active cardiac disease not controlled by therapy

          -  No myocardial infarction within the past 12 months

        PRIOR CONCURRENT THERAPY:

          -  No prior chemotherapy or radiotherapy for NSCLC

          -  No other concurrent systemic chemotherapy, investigational drug, or radiotherapy
Clinical trial NCT00721747 (phase 2, status: unknown status)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: docetaxel, liposomal doxorubicine and cyclophosphamide
SMILES: ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

          -  Brest adenocarcinoma stages II/III

          -  Female

          -  Informed consent signed

          -  HER2 negative

          -  Age>18 years old

          -  ECOG < 1

          -  Proper organic function regarding the following criteria:

               1. ANC > 2,0 x 109L, platelets > 100 x 109L and hemoglobin > 10g/dL (transfusion is
                  allowed)

               2. Hepatic Function:

             i.Bilirubin < 1,5 x UNL ii.AST ,ALT < 2,5 x UNL iii.Alkaline phosphatase < 5 UNL
             iv.Patients with AST and /or ALT > 1.5 x UNL and alkaline phosphatase > 2.5 x UNL will
             not be selected for the study c.Renal function: creatinine < 1,25 x UNL, or creatinine
             clearance > 60 mL/min d.Normal Cardiac function, confirmed with FEVI >50% and
             electrocardiogram.

          -  Patients should be available for treatment and follow up and must be treated in
             investigator or co-investigator site

          -  Negative pregnancy test(performed 7 days before treatment)

        Exclusion Criteria:

          -  Previous treatment for breast cancer (CT, RT, IT, HT)

          -  Stages IIIb, IIIc or IV or invasive bilateral breast cancer

          -  Previous neoplasias treated with Anthracyclines or Taxanes (Paclitaxel or Docetaxel)

          -  Pregnant or breastfeeding females

          -  Neurotoxicity Grade 2

          -  FEV≤50% or any cardiac disease in which anthracyclines are contraindicated

          -  Other severe diseases regarding investigator criteria

          -  Any neurological or psychiatric pathology

          -  Previous neoplasia different from breast cancer except:

               1. skin cancer(no melanoma)

               2. In situ cervix Carcinoma

               3. Ipsilateral in situ ductal carcinoma

               4. In situ lobular in situ carcinoma

               5. Any other carcinoma without evidence disease in last 10 years

          -  Treatment chronic with corticoids (except patients starting 6 months before inclusion
             with low dosages (* 20 mg methylprednisolone or equivalent)

          -  Concomitant treatment with Hormone ovarian replacement therapy

          -  Contraindication for corticoids

          -  Concomitant treatment with another investigational drugs

          -  Included in another clinical trial with any drug in 30 days before inclusion study

          -  Concomitant treatment with another anticancer therapy

          -  Male patients

          -  Hypersensibility to any study drug or components
Clinical trial NCT00514761 (phase 2, status: completed)
Conditions: metastatic colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: azd6244, capecitabine
SMILES: CN1C=NC2=C1C=C(C(O)=NOCCO)C(NC1=C(Cl)C=C(Br)C=C1)=C2F, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  colorectal cancer

          -  require treatment but have failed one or two previous chemotherapeutic regimens that
             must have included oxaliplatin and/or irinotecan

          -  have World Health Organisation (WHO) performance status 0-2 and life expectancy > 12
             weeks

        Exclusion Criteria:

          -  previous therapy with EGFR inhibitor, MEK inhibitor or capecitabine

          -  any recent surgery, unhealed surgical incision or severe concomitant condition which
             makes it undesirable for the patient to participate in the study

          -  nausea and vomiting, chronic gastrointestinal disease or significant bowel resection
             that would preclude adequate absorption
Clinical trial NCT01447706 (phase 2, status: completed)
Conditions: epithelial ovarian cancer, fallopian tube cancer, peritoneal cancer
ICD codes: H18.523, H18.521, H18.522, H18.529, C57.00, C57.01, C57.02, K65.1, K66.0, N99.4, N73.6, R88.0, Z49.32, Z49.02
Drugs: mm-121, paclitaxel
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Locally advanced/metastatic or recurrent epithelial ovarian cancer, fallopian tube
             cancer or primary peritoneal cancer

          -  Received at least one prior platinum based chemotherapy regimen

          -  Platinum-resistant or refractory

          -  Eligible for weekly paclitaxel

          -  Adequate liver and kidney function

          -  18 years of age or above

        Exclusion Criteria:

          -  Evidence of any other active malignancy

          -  History of severe allergic reactions to paclitaxel or other drugs formulated in
             Cremophor®EL
Clinical trial NCT00319839 (phase 2, status: terminated)
Conditions: head and neck cancer
ICD codes: C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11
Drugs: abraxane, cetuximab
SMILES: [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C, [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  All patients must have histologically or cytologically confirmed carcinoma of the head
             and neck region. Primary tumor sites include: lip and oral cavity, major salivary
             glands, pharynx (oropharynx, nasopharynx, hypopharynx), or larynx (supraglottis,
             glottis, subglottis), nasal cavity and paranasal sinuses, and thyroid

          -  Patients must have metastatic or locally recurrent squamous cell carcinoma of the head
             and neck. Patients with locoregional disease must be considered incurable by means of
             locoregional therapy.

          -  All sites of disease must be assessed and designated as measurable or non-measurable
             disease as documented by CT, MRI, X-ray physical exam or nuclear exam. All measurable
             and non-measurable disease must be assessed within 28 days prior to registration.

          -  Patients may have prior chemotherapy for recurrent/metastatic disease. However, all
             chemotherapy must be completed at least 21 days prior to scheduled start of Abraxane.

          -  Patients must have adequate bone marrow reserve as documented by absolute neutrophil
             count (ANC) > 1,500 μl and platelets > 100,000/ μl obtained within 14 days prior to
             registration.

          -  Patients must have adequate hepatic as documented by serum bilirubin < 1.5 x the
             institutional upper limit of normal. These tests must be obtained within 14 days prior
             to registration.

          -  All patients must be 18 years of age or older

          -  Patients must have a Zubrod performance of 0-3

        Exclusion Criteria:

          -  Patients must not have prior therapy with Abraxane

          -  Patients with any evidence of active or uncontrolled infection, recent myocardial
             infection, unstable angina, or life-threatening arrhythmia are not eligible.

          -  Patients with baseline grade 3 peripheral neuropathy are not eligible.

          -  Patients with known brain metastasis are not eligible. However, brain-imaging studies
             are not required for eligibility if the patient has no neurological signs or symptoms.
             If brain-imaging studies are performed, they must be negative for disease.
Clinical trial NCT01318135 (phase 2/phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: alogliptin and glimepiride, alogliptin and glimepiride, alogliptin and metformin, alogliptin and metformin
SMILES: [H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1, [H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1, CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

        Common criteria that applied to participants completing both the core phase 2/3
        sulfonylurea add-on study and those completing the core phase 2/3 metformin add-on study:

          1. Had completed the core phase 2/3 sulfonylurea add-on study or the core phase 2/3
             metformin add-on study.

          2. Was capable of understanding and complying with protocol requirements.

          3. Signed a written informed consent form prior to the initiation of any study procedure.

        Exclusion Criteria:

        Common criteria that applied to participants completing both the core phase 2/3
        sulfonylurea add-on study and those completing the core phase 2/3 metformin add-on study:

          1. With clinical manifestation of hepatic impairment (eg, an aspartate aminotransferase
             or alanine aminotransferase value of 2.5 times or more of the upper reference limit at
             Week 8 of the core phase 2/3 sulfonylurea add-on study or the core phase 2/3 metformin
             add-on study).

          2. With clinical manifestation of renal impairment (eg, a creatinine value of 1.5 times
             or more of the upper reference limit at Week 8 of the core phase 2/3 sulfonylurea
             add-on study or the core phase 2/3 metformin add-on study).

          3. With serious cardiac disease, cerebrovascular disorder, or serious pancreatic or
             hematological disease (eg, a subject who requires hospital admission).

        Criteria that applied only to participants completing the core phase 2/3 metformin add-on
        study:

        1. With history or symptoms of lactic acidosis.